Vestal Point Capital, LP - Significant Ownership

Signature - Title
/s/ Ryan Wilder - By: Vestal Point Capital, LLC, General Partner, By: Ryan Wilder, Chief Investment Officer and Managing Partner
Location
New York, NY
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Vestal Point Capital, LP.

Email me when Vestal Point Capital, LP files a new Schedule 13D/G report.

⭐ Subscribe ⭐

Significant Ownership of Vestal Point Capital, LP

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
TENX TENAX THERAPEUTICS, INC. Common Stock, par value $0.0001 per share 9.9% $18.5M 2.47M Vestal Point Capital, LP Sep 30, 2024
APLT Applied Therapeutics, Inc. Common Stock, par value $0.0001 per share 9.9% $4.49M 11.5M Vestal Point Capital, LP Dec 31, 2024
IBIO iBio, Inc. Common Stock, par value $0.001 per share 9.9% $3.52M 4.28M Vestal Point Capital, LP Sep 30, 2025
BCAX Bicara Therapeutics Inc. Common Stock, par value $0.0001 per share 9.2% $48.6M $21.7M 5M +80.6% Vestal Point Capital, LP Jun 30, 2025
ATXS Astria Therapeutics, Inc. Common Stock, par value $0.001 per share 8.8% $36.1M 4.96M Vestal Point Capital, LP Sep 30, 2025
LXEO Lexeo Therapeutics, Inc. Common Stock, par value $0.0001 per share 7.5% $27.3M $5.9M 4.12M +27.5% Vestal Point Capital, LP Sep 30, 2025
IMTX Immatics N.V. Ordinary Shares, nominal value 0.01 euro per share 5.3% $30.6M 6.28M Vestal Point Capital, LP Dec 31, 2024
TYRA Tyra Biosciences, Inc. Common Stock, par value $0.0001 per share 4.5% $33.9M -$6.36M 2.43M -15.8% Vestal Point Capital, LP Sep 30, 2025
NYXH Nyxoah SA Ordinary Shares, no nominal value per share 3.7% $10.6M -$6.93M 1.4M -39.5% Vestal Point Capital, LP Jun 30, 2025
DNTH Dianthus Therapeutics, Inc. /DE/ Common Stock, par value $0.001 per share 3% $46.4M -$79.5M 1.18M -63.1% Vestal Point Capital, LP Sep 30, 2025
SVRA Savara Inc Common Stock, par value $0.001 per share 2.3% $14.3M -$24.1M 4.02M -62.7% Vestal Point Capital, LP Sep 30, 2025
SLDB Solid Biosciences Inc. Common Stock, par value $0.001 per share 2.3% $6.44M 1.75M Vestal Point Capital, LP Mar 31, 2025
KALV KalVista Pharmaceuticals, Inc. Common Stock, par value $0.001 per share 1.5% $9.14M 750K Vestal Point Capital, LP Sep 30, 2025
QURE uniQure N.V. Ordinary Shares, par value 0.05 euro per share 0.4% $13.1M -$203M 225K -93.9% Vestal Point Capital, LP Sep 30, 2025

Schedules 13D/G Reported by Vestal Point Capital, LP:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Date Filed
* An asterisk sign (*) next to the price indicates that the price is likely invalid.